ES2077086T3 - Vesiculas de membrana sintetica que contienen peptidos de fusion funcionalmente activos como sistemas de suministro de farmacos. - Google Patents
Vesiculas de membrana sintetica que contienen peptidos de fusion funcionalmente activos como sistemas de suministro de farmacos.Info
- Publication number
- ES2077086T3 ES2077086T3 ES91101414T ES91101414T ES2077086T3 ES 2077086 T3 ES2077086 T3 ES 2077086T3 ES 91101414 T ES91101414 T ES 91101414T ES 91101414 T ES91101414 T ES 91101414T ES 2077086 T3 ES2077086 T3 ES 2077086T3
- Authority
- ES
- Spain
- Prior art keywords
- membrane
- weight
- phospholipid
- cell
- detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Feedback Control In General (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Air Conditioning Control Device (AREA)
Abstract
LAS VESICULAS FOSFOLIPIDAS BICAPA CONTIENEN AL MENOS UN MEDICAMENTO FARMACEUTICAMENTE ACTIVO Y COMPRENDEN MARCADORES ESPECIFICOS DE CELULAS EN LA MEMBRANA QUE TIENE AL MENOS UN 90% DE ACTIVIDAD BIOLOGICA CUANDO SE MIDEN DE ACUERDO CON LA INVESTIGACION ANTIVIRICA 14, 39-50 DE LUESCHERY GLUECK. EN LA MEMBRANA, EL CONTENIDO DE COLESTEROL ES PREFERENTEMENTE MENOR DEL 2% EN PESO, EL CONTENIDO DE DETERGENTE PREFERENTEMENTE MENOR DE 1PPB. EL DIAMETRO DE LA VESICULA ES PREFERENTEMENTE DE 8 NM APROXIMADAMENTE. EL FOSFOLIPIDO EN LA MEMBRANA PUEDE COMPRENDER DEL 70 A 95% EN PESO DE FOSFATIDICOLINA Y PREFERENTEMENTE DEL 10 AL 20% EN PESO DE FOSFATIDILETANOLAMINA; PREFERIBLEMENTE DEL 6 AL 8% EN PESO DE UN RETICULADOR PREFERIBLEMENTE DE UN DERIVADO SULFOSUCINIMIDILA, Y AL MENOS UN PEPTIDO DE FUSION ESPECIFICA CELULAR ESTA ENLAZADO A LA MEMBRANA. LAS VESICULAS SE UTILIZAN PARA LA PREPARACION DE FARMACOS CONTRA EL SIDA Y LOS CARCIHOMAS. EL PROCESO PARA LA PREPARACION DE VESICULAS BICAPA FOSFOLIPIDAS COMPRENDE HEMAGLUTININA COMO MARCADOR ESPECIFICO CELULAR CON AL MENOS UN PEPTIDO DE FUSION. LA HEMAGLUTININA SE SEPARA DE UNA CAPA DE VIRUS POR MEDIO DE UN DETERGENTE NORONICO, PREFERIBLEMENTE ESTEN MONODODECILO GLICOL OCTAETILENO. SE EXTRAE MEDIANTE EL TRATAMIENTO REPETITIVO DE LA SOLUCION CON UN TOTAL DE ALREDEDOR DE 15 G DE MICROPORTADORES EN BOLAS DE POLIESTIRENO POR 100 MG DE DETERGENTE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91101414A EP0497997B1 (en) | 1991-02-02 | 1991-02-02 | Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2077086T3 true ES2077086T3 (es) | 1995-11-16 |
Family
ID=8206362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91101414T Expired - Lifetime ES2077086T3 (es) | 1991-02-02 | 1991-02-02 | Vesiculas de membrana sintetica que contienen peptidos de fusion funcionalmente activos como sistemas de suministro de farmacos. |
Country Status (22)
Country | Link |
---|---|
US (1) | US6040167A (es) |
EP (1) | EP0497997B1 (es) |
JP (1) | JP3404037B2 (es) |
KR (1) | KR100205693B1 (es) |
AT (1) | ATE125154T1 (es) |
AU (1) | AU657730B2 (es) |
BG (1) | BG61215B1 (es) |
BR (1) | BR9204116A (es) |
CA (1) | CA2079685C (es) |
DE (1) | DE69111414T2 (es) |
DK (1) | DK0497997T3 (es) |
ES (1) | ES2077086T3 (es) |
FI (1) | FI109969B (es) |
GE (1) | GEP20002229B (es) |
GR (1) | GR3017490T3 (es) |
HK (1) | HK56696A (es) |
HU (1) | HU215533B (es) |
NO (1) | NO306194B1 (es) |
PL (2) | PL296382A1 (es) |
RO (1) | RO114736B1 (es) |
RU (1) | RU2125868C1 (es) |
WO (1) | WO1992013525A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2079444C (en) * | 1991-02-14 | 2004-02-03 | Rimona Margalit | Binding of recognizing substances to liposomes |
US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
WO1995032706A1 (en) * | 1994-05-31 | 1995-12-07 | Inex Pharmaceuticals Corp. | Virosome-mediated intracellular delivery of therapeutic agents |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
WO1997004748A2 (en) * | 1995-08-01 | 1997-02-13 | Advanced Therapies, Inc. | Enhanced artificial viral envelopes for cellular delivery of therapeutic substances |
NZ332666A (en) * | 1996-05-08 | 2000-05-26 | Nika Health Products Ltd | Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy |
JP2002532514A (ja) * | 1998-12-14 | 2002-10-02 | デンドレオン コーポレイション | 主要組織適合性複合体クラスi拘束抗原提示の増強のための、組成物および方法 |
US7148324B1 (en) | 1998-12-14 | 2006-12-12 | Dendreon Corporation | Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation |
EP1140202A1 (en) | 1998-12-24 | 2001-10-10 | Ucb S.A. | Peptidic product, process and composition |
CZ20021216A3 (cs) * | 1999-10-08 | 2002-10-16 | Nika Health Products Limited | Lipidové váčky obsahující DOSPER |
ES2202218T3 (es) * | 1999-12-17 | 2004-04-01 | Schott Glas | Capsula fulminante activable inductivamente para sistemas de retencion de pasajeros y circuito de prueba para esta capsula fulminante. |
US20040028687A1 (en) * | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
US20040176283A1 (en) * | 2002-04-01 | 2004-09-09 | Robinson John A. | Methods and compositions for the design of synthetic vaccines |
DE50312971D1 (de) * | 2002-04-29 | 2010-09-23 | Biotesys Gmbh | Polymerisierte peptid-modifizierte lipide als biologische transportsysteme für mikronutrients |
EP1447080A1 (en) | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
CN103948545B (zh) | 2004-05-03 | 2017-10-03 | 益普生生物制药公司 | 用于药物输送的脂质体 |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
WO2007048019A2 (en) * | 2005-10-20 | 2007-04-26 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
CN105769931B (zh) * | 2006-09-15 | 2021-04-27 | 渥太华医院研究机构 | 溶瘤弹状病毒 |
EP3362049A1 (en) | 2015-10-16 | 2018-08-22 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0047480B1 (en) * | 1980-09-05 | 1986-02-05 | Institut Armand Frappier | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane |
US4871488A (en) * | 1985-04-22 | 1989-10-03 | Albany Medical College Of Union University | Reconstituting viral glycoproteins into large phospholipid vesicles |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
IL86650A0 (en) * | 1987-06-30 | 1988-11-30 | Biophor Corp | Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane |
WO1991003258A1 (en) * | 1989-09-01 | 1991-03-21 | Board Of Regents, The University Of Texas System | Immunoliposomes for transmittal of activating signals to cells |
AU652778B2 (en) * | 1990-10-15 | 1994-09-08 | Quest International B.V. | Treatment composition |
-
1991
- 1991-01-17 PL PL29638291A patent/PL296382A1/xx unknown
- 1991-02-02 DE DE69111414T patent/DE69111414T2/de not_active Expired - Fee Related
- 1991-02-02 AT AT91101414T patent/ATE125154T1/de not_active IP Right Cessation
- 1991-02-02 ES ES91101414T patent/ES2077086T3/es not_active Expired - Lifetime
- 1991-02-02 EP EP91101414A patent/EP0497997B1/en not_active Expired - Lifetime
- 1991-02-02 DK DK91101414.0T patent/DK0497997T3/da active
-
1992
- 1992-01-17 CA CA002079685A patent/CA2079685C/en not_active Expired - Fee Related
- 1992-01-17 US US07/930,593 patent/US6040167A/en not_active Expired - Fee Related
- 1992-01-17 AU AU11693/92A patent/AU657730B2/en not_active Ceased
- 1992-01-17 RO RO92-01271A patent/RO114736B1/ro unknown
- 1992-01-17 HU HU9203141A patent/HU215533B/hu not_active IP Right Cessation
- 1992-01-17 BR BR929204116A patent/BR9204116A/pt not_active Application Discontinuation
- 1992-01-17 GE GEAP19921215A patent/GEP20002229B/en unknown
- 1992-01-17 RU SU5053247A patent/RU2125868C1/ru not_active IP Right Cessation
- 1992-01-17 JP JP50347192A patent/JP3404037B2/ja not_active Expired - Fee Related
- 1992-01-17 WO PCT/EP1992/000089 patent/WO1992013525A1/en active IP Right Grant
- 1992-01-17 PL PL92296382A patent/PL170169B1/pl not_active IP Right Cessation
- 1992-09-24 NO NO923703A patent/NO306194B1/no not_active IP Right Cessation
- 1992-09-29 BG BG96928A patent/BG61215B1/bg unknown
- 1992-10-01 FI FI924418A patent/FI109969B/fi active
- 1992-10-01 KR KR1019920702402A patent/KR100205693B1/ko not_active IP Right Cessation
-
1995
- 1995-09-21 GR GR950402607T patent/GR3017490T3/el unknown
-
1996
- 1996-03-28 HK HK56696A patent/HK56696A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL170169B1 (en) | 1996-10-31 |
JP3404037B2 (ja) | 2003-05-06 |
CA2079685C (en) | 2001-11-27 |
KR100205693B1 (en) | 1999-07-01 |
BG96928A (bg) | 1994-03-24 |
ATE125154T1 (de) | 1995-08-15 |
FI109969B (fi) | 2002-11-15 |
RU2125868C1 (ru) | 1999-02-10 |
BG61215B1 (en) | 1997-03-31 |
EP0497997A1 (en) | 1992-08-12 |
NO306194B1 (no) | 1999-10-04 |
AU1169392A (en) | 1992-09-07 |
BR9204116A (pt) | 1993-06-08 |
HU9203141D0 (en) | 1992-12-28 |
GEP20002229B (en) | 2000-09-25 |
NO923703L (no) | 1992-11-26 |
RO114736B1 (ro) | 1999-07-30 |
DE69111414T2 (de) | 1996-02-01 |
US6040167A (en) | 2000-03-21 |
JPH05505406A (ja) | 1993-08-12 |
NO923703D0 (no) | 1992-09-24 |
FI924418A (fi) | 1993-04-03 |
DE69111414D1 (de) | 1995-08-24 |
DK0497997T3 (da) | 1995-11-27 |
EP0497997B1 (en) | 1995-07-19 |
GR3017490T3 (en) | 1995-12-31 |
HK56696A (en) | 1996-04-12 |
HUT66194A (en) | 1994-10-28 |
CA2079685A1 (en) | 1992-08-03 |
FI924418A0 (fi) | 1992-10-01 |
PL296382A1 (en) | 1993-11-02 |
WO1992013525A1 (en) | 1992-08-20 |
AU657730B2 (en) | 1995-03-23 |
HU215533B (hu) | 1999-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2077086T3 (es) | Vesiculas de membrana sintetica que contienen peptidos de fusion funcionalmente activos como sistemas de suministro de farmacos. | |
US5366737A (en) | N-[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor | |
Egbaria et al. | Liposomes as a topical drug delivery system | |
Mizuguchi et al. | Efficient gene transfer into mammalian cells using fusogenic liposome | |
US4789633A (en) | Fused liposome and acid induced method for liposome fusion | |
AU697484B2 (en) | Preparation of multivesicular liposomes for controlled release of active agents | |
Mayhew et al. | Inhibition of Tumor Cell Growth in vitro and in vivo by 1-β-D-arabinofuranosylcytosine Entrapped within Phospholipid Vesicles | |
FR2635265B1 (fr) | Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation | |
US4148876A (en) | Biological preparations | |
NZ332666A (en) | Cationic virosomes having a positively charged lipid bilayer membrane with an integrated viral fusogenic peptide as genetic transfer systems for use in gene therapy | |
Jain et al. | Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism | |
Scheule | Novel preparation of functional Sindbis virosomes | |
GB1564500A (en) | Biological preparations | |
ES2093701T3 (es) | Procedimiento para la preparacion de suspensiones acuosas de liposomas que contienen sustancias activas. | |
ES2122962T3 (es) | Derivados de alquileno-dioxibenceno opticamente activos y su uso en terapia. | |
Wood et al. | Transmembrane orientation of lipophilin in phosphatidylcholine vesicles | |
Halstrom et al. | N-2-nitrophenylsulfenyl amino acid N-carboxy anhydrides | |
ATE61222T1 (de) | Aspoxicillin enthaltende medizinalzubereitung, ein verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels. | |
Jaafari et al. | Targeting of Liposomes to Human Keratinocytes Through Adhesive Peptides from Immunoglobulin Domains in the Presence of IFNM-γ | |
Jansons et al. | Liposomes as a means to introduce fragment A of diphtheria toxin into cells | |
BRANT et al. | Shuttle vector plasmid propagation in human peripheral blood lymphocytes facilitated by liposome-mediated transfection | |
Fountain et al. | Liposome carrier vehicle for triiodothryonine | |
Kumar et al. | Pentobarbitone stimulation of protein phosphorylation in rat brain in vitro | |
Philippot et al. | LIPOSOMES as TOOLS in BASIC RESEARCH and | |
HU901875D0 (en) | Process for production of galenical preparations providing optimal biological accessibility of 2-hydroxi-5-methyl-laurophenon-oxim as active substance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 497997 Country of ref document: ES |